Q2 EPS Forecast for BriaCell Therapeutics Raised by Analyst

BriaCell Therapeutics Corp. (NASDAQ:BCTX) – Analysts at HC Wainwright lifted their Q2 2025 earnings estimates for shares of BriaCell Therapeutics in a note issued to investors on Monday, February 3rd. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings per share of ($1.94) for the quarter, up from their previous forecast of ($4.05). HC Wainwright currently has a “Buy” rating and a $32.00 target price on the stock. The consensus estimate for BriaCell Therapeutics’ current full-year earnings is ($15.14) per share. HC Wainwright also issued estimates for BriaCell Therapeutics’ Q3 2025 earnings at ($1.12) EPS, Q4 2025 earnings at ($1.14) EPS, FY2025 earnings at ($2.45) EPS, FY2026 earnings at ($1.47) EPS, FY2027 earnings at ($1.09) EPS, FY2028 earnings at ($0.69) EPS and FY2029 earnings at ($0.24) EPS.

BriaCell Therapeutics (NASDAQ:BCTX) last released its quarterly earnings data on Monday, December 16th. The company reported ($3.30) EPS for the quarter, missing the consensus estimate of ($1.20) by ($2.10).

BriaCell Therapeutics Price Performance

Shares of BriaCell Therapeutics stock opened at $4.10 on Wednesday. The business has a fifty day simple moving average of $8.95 and a two-hundred day simple moving average of $10.37. BriaCell Therapeutics has a 1 year low of $3.92 and a 1 year high of $65.25. The company has a market capitalization of $12.09 million, a price-to-earnings ratio of -0.31 and a beta of 1.59.

Institutional Investors Weigh In On BriaCell Therapeutics

A hedge fund recently bought a new stake in BriaCell Therapeutics stock. Vontobel Holding Ltd. acquired a new position in shares of BriaCell Therapeutics Corp. (NASDAQ:BCTX) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 80,000 shares of the company’s stock, valued at approximately $99,000. Vontobel Holding Ltd. owned 0.44% of BriaCell Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 15.42% of the company’s stock.

About BriaCell Therapeutics

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.